Clinical
Sirtex reports 100% tumor control in Y-90 HCC study
The 12-month results showed a 90% complete response rate and a 99% best overall response rate in patients with unresectable hepatocellular carcinoma.
Company
Sirtex
Clinical
Sirtex reports 100% local tumor control in HCC trial
The DOORwaY90 study reported a 90% complete response rate and 99% best overall response rate for SIR-Spheres Y-90 resin microspheres.